Trachoma: Recent developments

Advances in Experimental Medicine and Biology

Volumn 609, Issue , 2008, Pages 98-107

  Mabey, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

CHLAMYDIASIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONFERENCE PAPER; HEALTH PROGRAM; HUMAN; PATHOGENESIS; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SURGICAL TECHNIQUE; TRACHOMA; TRICHIASIS; WORLD HEALTH ORGANIZATION; CHLAMYDIA TRACHOMATIS; EYELID DISEASE; MICROBIOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY; REVIEW;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHLAMYDIA TRACHOMATIS; EYELID DISEASES; HUMANS; TRACHOMA;

EID: 39149093048     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-73960-1_8     Document Type: Conference Paper

References (51)

1. Alemayehu W, Melese M, Bejiga A, Worku A, Kebede W, and Fantaye D. (2004). Surgery for trichiasis by ophthalmologists versus integrated eye care workers. Ophthalmology, 111:578-584.
2. Batt SL, Charalombous BM, Solomon AW, Massae PA, Safari S, Sam N, Everett D, Knirsch C, Mabey DCW, and Gillespie SH. (2003). Impact of azithromycin administration for trachoma control on the carriage of antibiotic resistant Streptococcus pneumoniae. Antimicrob Agents Chemother, 47:2765-2769.
3. Bird M, Dawson CR, Schachter J, Miao Y, and Shama A et al. (2003). Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas? J Infect Dis, 187:1669-1673.
4. Burton MJ, Holland MJ, Faal N, Aryee E, Alexander NDE, Makalo P, Bah M, Faal H, West SK, Foster A, Johnson GJ, Mabey DCW, and Bailey RL. (2003). Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in a trachoma endemic Gambian community. Invest Ophthalmol Vis Sci, 44:4215-4222.
5. Burton MJ, Bailey RL, Jeffries D, Mabey DCW, and Holland MJ. (2004). Cytokine and fibrogenic gene expression in the conjunctiva of subjects from a trachoma endemic Gambian community. Infect Immun, 72:7352-7356.
6. Burton MJ, Holland MJ, Makalo P, Aryee EAN, Alexander NDE, Sillah A, Faal H, West SK, Foster A, Johnson GJ, Mabey DCW, and Bailey RL. (2005a). The impact of mass antibiotic treatment on Chlamydia trachomatis infection and its re-emergence in a trachoma endemic Gambian community. Lancet, 365:1321-1328.
7. Burton MJ, Bowman RJC, Faal H, Aryee EAN, Ikumapayi UN, Alexander NDE, Adegbola RA, West SK, Mabey DCW, Foster A, Johnson GJ, and Bailey RL. (2005b). Long-term outcome of trichiasis surgery in The Gambia. BJO, 89:574-579.
8. Burton MJ, Kinteh F, Jallow O, Sillah A, Bah M, Faye M, Aryee EAN, Ikumapayi N, Alexander NDE, Adegbola R, Faal H, Mabey DCW, Foster A, Johnson GJ, and Bailey RL. (2005c). A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in The Gambia. BJO, 89:1282-1288.
9. Burton MJ, Holland MJ, Jeffries D, Johnson GJ, Mabey DCW, and Bailey RL. (2006). Identifying productive conjunctival Chlamydia trachomatis infections. Measurement of chlamydial 16S rRNA expression in the members of a trachoma endemic Gambian community. Clin Infect Dis, 42:463-470.
10. Caldwell HD, Wood H, Crane D, Bailey R, Jones RB, Mabey D, Maclean I, Mohammed Z, Peeling R, Roshick C, Suchland RJ, Stamm WE, Taylor L, West SK, Quinn TC, Beiland RJ, and McClarty G. (2003). Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiates between genital and ocular isolates. Implications in pathogenesis and infection tropism. J Clin Invest, 111:1757-1769.
11. Chami Y, Hammou J, and Mahjour J. (2004). Lessons from the Moroccan National Trachoma Control Programme. Community Eye Health, 17:59.
12. Chidambaram JD, Bird M, Schiedler V, Fry AM, Porco T, Bhatta RC, Jha H, Chaudary JSP, Gaynor B, Yi E, Whitcher JP, Osaki-Holm S, and Lietman TM. (2004). Trachoma decline and widespread use of antimicrobial drugs. Emerg Infect Dis, 10:1895-1899.
13. Chidambaram J, Lee D, Porco T, and Lietman T. (2005). Mass antibiotics for trachoma and the Allee effect. Lancet Infect Dis, 5:194-196.
14. Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, House J, Cevallos V, Zhou Z, Maxey K, Lee DC, Shapiro BL, Srinivasan M, Porco T, Whitcher JP, Gaynor BD, and Lietman TM. (2006). Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA, 295:1142-1146.
15. Cumberland P., Hailu G, and Todd J. (2005). Active trachoma in children aged three to nine years in rural communities in Ethiopia: prevalence, indicators and risk factors. Trans R Soc Trop Med Hyg, 99:120-127.
16. Desmond N, Solomon A, Massae P, Lema N, Anemona A, Foster A, and Mabey D. (2005). An examination of the acceptability of azithromycin in the control of trachoma in Northern Tanzania. Trans R Soc Trop Med Hyg, 99:656-663.
17. Dolin PJ, Faal H, Johnson GJ, Ajewole J, Mohamed AA, and Lee PL. (1998). Trachoma in the Gambia. Br J Ophthalmol, 82:930-933.
18. Faal N, Bailey RL, Sarr I, Joof H, Mabey DCW, and Holland MJ. (2005). Temporal cytokine gene expression patterns in subjects with trachoma identify distinct conjunctival responses associated with infection. Clin Exp Immunol, 142:347-353.
19. Fry AM, Jha HC, Lietman TM, Chaudhary JSP, Bhatta RC, Elliott J, Hyde T, Schuchat A, Gaynor B, and Dowell SF. (2002). Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis, 35:395-402.
20. Gaynor B, Zegans M, Bird M, Yi E, Holbrook K, Whitcher JP, and Lietman T. (2002). Disappearance of trachoma from Western Nepal. Clin Infect Dis, 35:765-768.
21. Gaynor BD, Holbrook KA, Whitcher JP, Holm SO, Jha HC, Chaudhary JSP, Bhatta RC, and Lietman T. (2003). Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. BJO, 97:147-148.
22. Harding-Esch E, Solomon A, Massae P, and Mabey D. (2006). Five year impact of mass azithromycin treatment on trachoma in Rombo District, Tanzania. In Chernesky M et al. (eds.), Chlamydial Infections. Proceedings of the Eleventh International Symposium on Human Chlamydial Infections. Niagara on the Lake, Canada, June 18th-23rd, pp. 333-336.
23. Holland MJ, Faal N, Sarr I, Joof H, Cameron E, Pemberton-Pigott F, Dockrell HM, Bailey RL, and Mabey DCW (2006). The frequency of Chlamydia trachomatis major outer membrane protein specific CD8+ T lymphocytes in active trachoma is associated with current ocular infection. Infect Immun, 74:1565-572.
24. Jha H, Chaudary JS, Bhatta R, Miao Y, Osaki-Holm S, Gaynor B, Zegans M, Bird M, Yi E, Holbrook K, Whitcher JP, Lietman T. (2002). Disappearance of trachoma from Western Nepal. Clin Infect Dis, 35:765-8.
25. Kuper H, Solomon AW, Zondervan M, Buchan J, Mabey D, and Foster A. (2005). Participatory evaluations of trachoma control programmes in eight countries. TMIH, 8:264-272.
26. Mabey D and Solomon AW. (2003). Application of molecular tools in the control of Blinding Trachoma. Am J Trop Med Hyg, 69 (Suppl 5): 11-17.
27. Mabey D, Solomon A, and Foster A. (2003). Trachoma seminar. Lancet, 362:223-229.
28. Melese M, Chidambaran JD, Alemayehu W, Lee DC, Yi EH, Cevallos V, Zhou Z, Donnellan C, Saidel M, Whitcher JP, Gaynor BD, and Lietman TM. (2004). Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA, 292:721-725.
29. Michel CEC, Solomon AW, Magbanua JPV, Massae PA, Huang L, Mosha J, West SK, Nadala ECB, Bailey R, Wisniewski C, Mabey DCW, and Lee HH. (2006). A rapid point-of-care assay for targeting antibiotic treatment to eliminate trachoma. Lancet, 367:1585-1590.
30. Miller K, Schmidt G, Melese M, Alemayehu W, and Yi E. et al. (2004). How reliable is the clinical exam in detecting ocular chlamydial infection? Ophthalmic Epidemiol, 11:255-262.
31. Munoz B, Solomon A, Zingeser J, Barwick R, Burton M, Bailey R, Foster A, Mabey D, and West SK. (2003). Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children. Invest Ophthalmol Vis Sci, 44 1464-1469.
32. Natividad-Sancho A, Bailey R, Holland M., Kwiatkowski D, and Mabey D. (2005). Susceptibility to trachomatous scarring and trichiasis is associated with Interferon gamma (IFNγ) and Interleukin 10 (IL10) gene single nucleotide polymorphism (SNP) haplotypes. Genes Immun, 6:332-340.
33. Natividad A, Holland MJ, Rockett KA, Joof HM, Mabey DCW, Bailey RL, and Kwiatkowski DP. (2006). Clinical consequences of allelic variation in the cis-regulation of IL10 during active trachomatous disease in humans. In Chernesky M et al. (eds.), Chlamydial Infections. Proceedings of the Eleventh International Symposium on Human Chlamydial Infections. Niagara on the Lake, Canada, June 18th-23rd, pp. 555-558.
34. Ngondi J, Onsarigo A, Adamu L, Matende I, Baba S, Reacher M, Emerson P, Zingeser J. (2005). The epidemiology of trachomo in Eastern Equatoria and Upper Nile States, southern Sudan. Bull World Health Organ, 83:904-12.
35. Polack S, Brooker S, Kuper H, Mabey D, and Foster A. (2005). The global distribution of trachoma. Bull World Health Organ, 83:913-919.
36. Ranson MK and Evans TG. (2003). The global burden of trachomatous visual impairment: 1. Assessing prevalence. Int Ophthalmol, 19:261-270.
37. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, and Mariotti SP. (2004). Global data on visual impairment in the year 2002. Bull World Health Organ, 82:844-851.
38. Saal M, Schemann J, Saar B, Faye M, Momo G, and Mariotti SP. (2003). Trachoma in Senegal: findings of a national survey. Med Trop (Mars), 63:53-59.
39. Schemann JF, Sacko D, Banou A, Bamani S, More B, and Coulibaly S. (1998). Cartography of trachoma in Mali: results of a national survey. Bull World Health Organ, 76:599-606
40. Schemann JF, Guinot C, Ilboudo L, Momo G, Ko B, and Sanfo O. (2003). Trachoma, flies and environmental factors in Burkina Faso. Trans R Soc Trop Med Hyg, 97:63-68.
41. Solomon AW, Holland MJ, Burton MJ, West SK, Alexander NDE, Aguirre A, Massae PA, Mkocha H, Munoz B, Johnson GJ, Peeling RW, Bailey RL, Foster A, and Mabey DCW (2003). Strategies for control of trachoma: observational study with quantitative PCR. Lancet, 362:198-204.
42. Solomon AW, Foster A, Peeling RW, and Mabey DCW. (2004a). Diagnosis and assessment of trachoma. Clin Microbiol Rev, 17:982-1011.
43. Solomon AW, Holland MJ, Alexander NDE, Massae PA, Aguirre A, Natividad-Sancho A, Molina S, Safari S, Shao JF, Peeling RW, West SK, Bailey RL, Foster A, and Mabey DCW. (2004b). Mass treatment with single-dose azithromycin for trachoma. N Engl J Med, 351:1962-1971.
44. Solomon AW, Mohammed Z, Massae PA, Shao JF, Foster A, Maclean IW, Mabey DCW, and Peeling RW. (2005). Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. Antimicrob Agents Chemother, 49:4804-4806.
45. Them J, Zhao P, Liu H, Xu J, and Jha H et al. (2002). Does clinical diagnosis indicate ocular chlamydial infection in areas with a low prevalence of trachoma? Ophthalmic Epidemiol, 9:263-269.
46. Thylefors B, Negrel AD, Pararajasegaram R, and Dadzie KY. (1995). Global data on blindness. Bull World Health Organ, 73:115-121.
47. West ES, Mkocha H, Munoz B, Mabey D, Bailey R, and West SK. (2005a). Risk factors for post-surgical trichiasis recurrence in a trachoma-endemic area. Invest Ophthalmol Vis Sci, 46:447-453.
48. West ES, West SK, Munoz B, Mkocha H, Holland MJ, Aguirre A, Solomon AW, Bailey R, Foster A, and Mabey D. (2005b). Mass treatment and the effect on the load of C trachomatis infection in a trachoma hyperendemic community. Invest Ophthalmol Vis Sci, 46:83-87.
49. West S, Munoz B, Mkocha H, Duncan D, Solomon AW, Holland M., Beltran A, Foster A, Bailey R, and Mabey D. (2005). Infection with C. trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania. Lancet, 366:1296-1300.
50. West SK, West ES, Alemayehu W, Melese M, Munoz B, Imeru A, Worku A, Gaydos C, Meinert CL, and Quinn T. (2006). Single-dose azithromycin prevents trichiasis recurrence following surgery: randomised trial in Ethiopia. Arch Ophthalmol, 124: 309-314.
51. World Health Organisation (2004). Report of the eighth meeting of the WHO alliance for the elimination of blinding trachoma. World Health Organisation, Geneva, WHO/PBD/GET/04.2.